BACKGROUND: Prostate cancer is an androgen dependent tumor. In advanced prostate cancers androgen deprivation has proved to be an effective therapy, but 25% show no response. In this study prostatectomy specimens from patients without preoperative therapy were analyzed to determine the possible mechanism of primary antiandrogen resistance. METHODS: The number of androgen receptor (AR) gene copies and X-centromeres were investigated from 80 prostate cancer specimens by FISH analysis. RESULTS: In 9 out of 80 prostate cancers additional X-chromosomes with the corresponding AR gene could be detected. Polysomy of the X-chromosome correlates with pathological classification and tumor volume. CONCLUSIONS: Additional AR genes due to polysomy of the X-chromosome are present in a subgroup of primary prostate cancers prior to antiandrogen therapy. Because the growth of prostate cancers is androgen dependent, these specimens may have an advantage in low concentrations of androgens. This may be a factor for initial antiandrogen resistance. Copyright 2003 Wiley-Liss, Inc.
BACKGROUND:Prostate cancer is an androgen dependent tumor. In advanced prostate cancers androgen deprivation has proved to be an effective therapy, but 25% show no response. In this study prostatectomy specimens from patients without preoperative therapy were analyzed to determine the possible mechanism of primary antiandrogen resistance. METHODS: The number of androgen receptor (AR) gene copies and X-centromeres were investigated from 80 prostate cancer specimens by FISH analysis. RESULTS: In 9 out of 80 prostate cancers additional X-chromosomes with the corresponding AR gene could be detected. Polysomy of the X-chromosome correlates with pathological classification and tumor volume. CONCLUSIONS: Additional AR genes due to polysomy of the X-chromosome are present in a subgroup of primary prostate cancers prior to antiandrogen therapy. Because the growth of prostate cancers is androgen dependent, these specimens may have an advantage in low concentrations of androgens. This may be a factor for initial antiandrogen resistance. Copyright 2003 Wiley-Liss, Inc.
Authors: Xiaoyu Qu; Claudio Jeldres; Lena Glaskova; Cynthia Friedman; Sarah Schroeder; Peter S Nelson; Christopher Porter; Min Fang Journal: J Mol Diagn Date: 2016-01-02 Impact factor: 5.568
Authors: Enrico Di Oto; Giovanni B Biserni; Zsuzsanna Varga; Luca Morandi; Maria C Cucchi; Riccardo Masetti; Maria P Foschini Journal: Virchows Arch Date: 2018-05-25 Impact factor: 4.064
Authors: Philipp Y Maximov; Balkees Abderrahman; Ramona F Curpan; Yousef M Hawsawi; Ping Fan; V Craig Jordan Journal: Endocr Relat Cancer Date: 2017-11-21 Impact factor: 5.678
Authors: Francis P Young; Therese M Becker; Mohammed Nimir; Thomas Opperman; Wei Chua; Bavanthi Balakrishnar; Paul de Souza; Yafeng Ma Journal: J Clin Med Date: 2022-01-04 Impact factor: 4.241